{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:55:33Z","timestamp":1790769333187,"version":"4.1.0"},"publisher-location":"New York, NY","reference-count":45,"publisher":"Springer US","isbn-type":[{"value":"9781071654750","type":"print"},{"value":"9781071654767","type":"electronic"}],"license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-1-0716-5476-7_10","type":"book-chapter","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:33:50Z","timestamp":1790764430000},"page":"161-170","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development of Antisense Oligonucleotide Gapmers for Amyotrophic Lateral Sclerosis"],"prefix":"10.1007","author":[{"given":"Yuriko","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Moriyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"10_CR1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1056\/NEJMra1705346","volume":"380","author":"AA Levin","year":"2019","unstructured":"Levin AA et al. (2019) Treating disease at the RNA level with oligonucleotides. N Engl J Med 380:57\u201370","journal-title":"N Engl J Med"},{"key":"10_CR2","doi-asserted-by":"publisher","first-page":"175628641877693","DOI":"10.1177\/1756286418776932","volume":"11","author":"CD Wurster","year":"2018","unstructured":"Wurster CD et al. (2018) Antisense oligonucleotides in neurological disorders. Ther Adv Neurol Disord 11:1756286418776932","journal-title":"Ther Adv Neurol Disord"},{"issue":"9","key":"10_CR3","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJM199403033300901","volume":"330","author":"G Bensimon","year":"1994","unstructured":"Bensimon G et al. (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 330(9):585\u2013591","journal-title":"N Engl J Med"},{"issue":"7-8","key":"10_CR4","doi-asserted-by":"publisher","first-page":"610","DOI":"10.3109\/21678421.2014.959024","volume":"15","author":"K Abe","year":"2014","unstructured":"Abe K et al. (2014) Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener 15(7-8):610\u2013617","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"5870","key":"10_CR5","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1126\/science.1154584","volume":"319","author":"Sreedharan","year":"2008","unstructured":"Sreedharan et al. (2008) TDP\u221243 mutations in familial and sporadic ALS. Science 319(5870):1668\u20131672","journal-title":"Science"},{"key":"10_CR6","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1056\/NEJMra1603471","volume":"377","author":"RH Brown","year":"2017","unstructured":"Brown RH (2017) Amyotrophic lateral sclerosis. N Engl J Med 377:162\u2013172","journal-title":"N Engl J Med"},{"issue":"7","key":"10_CR7","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1136\/jnnp-2016-315018","volume":"88","author":"Z Zhang-Yu","year":"2017","unstructured":"Zhang-Yu Z (2017) Genetic epidemiology of amyotrophic lateral sclerosis: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 88(7):540\u2013549","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10_CR8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1474-4422(24)00479-4","volume":"24","author":"B Michael","year":"2025","unstructured":"Michael B (2025) Amyotrophic lateral sclerosis caused by SOD1 variants: from genetic discovery to disease prevention. Lancet Neurol 24(1):77\u201386","journal-title":"Lancet Neurol"},{"issue":"2","key":"10_CR9","doi-asserted-by":"publisher","first-page":"e0247841","DOI":"10.1371\/journal.pone.0247841","volume":"16","author":"GRC Pereira","year":"2021","unstructured":"Pereira GRC et al. (2021) Comprehensive in silico analysis and molecular dynamics of the superoxide dismutase 1 (SOD1) variants related to amyotrophic lateral sclerosis. PLoS One 16(2):e0247841","journal-title":"PLoS One"},{"issue":"6415","key":"10_CR10","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/362059a0","volume":"362","author":"DR Rosen","year":"1993","unstructured":"Rosen DR (1993) Mutations in Cu\/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362(6415):59\u201362","journal-title":"Nature"},{"issue":"2","key":"10_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.gene.2015.11.049","volume":"577","author":"SJ Kaur","year":"2016","unstructured":"Kaur SJ (2016) Mutant SOD1 mediated pathogenesis of amyotrophic lateral sclerosis. Gene 577(2):109\u2013118","journal-title":"Gene"},{"issue":"6 Suppl 4","key":"10_CR12","first-page":"S233","volume":"47","author":"A Doble","year":"1996","unstructured":"Doble A (1996) The pharmacology and mechanism of action of riluzole. Neurology 47(6 Suppl 4):S233\u2013S241","journal-title":"Neurology"},{"issue":"15","key":"10_CR13","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1212\/WNL.0b013e3181bc01a4","volume":"73","author":"RG Miller","year":"2009","unstructured":"Miller RG (2009) Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review). Neurology 73(15):1218\u20131226","journal-title":"Neurology"},{"issue":"9","key":"10_CR14","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJM199403033300901","volume":"330","author":"G Bensimon","year":"1994","unstructured":"Bensimon G (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS\/Riluzole Study Group. N Engl J Med 330(9):585\u2013591","journal-title":"N Engl J Med"},{"issue":"9013","key":"10_CR15","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/S0140-6736(96)91680-3","volume":"347","author":"L Lacomblez","year":"1996","unstructured":"Lacomblez L (1996) Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis\/Riluzole Study Group II. Lancet 347(9013):1425\u20131431","journal-title":"Lancet"},{"issue":"7","key":"10_CR16","first-page":"61","volume":"29","author":"M Hinchcliffe","year":"2017","unstructured":"Hinchcliffe M (2017) Riluzole: real-world evidence supports significant extension of median survival times in patients with amyotrophic lateral sclerosis. Degener Neurol Neuromuscul Dis 29(7):61\u201370","journal-title":"Degener Neurol Neuromuscul Dis"},{"issue":"2","key":"10_CR17","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1001\/jamaneurol.2021.4893","volume":"79","author":"S Witzel","year":"2022","unstructured":"Witzel S (2022) Safety and effectiveness of long-term intravenous administration of edaravone for treatment of patients with amyotrophic lateral sclerosis. JAMA Neurol 79(2):121\u2013130","journal-title":"JAMA Neurol"},{"issue":"230","key":"10_CR18","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.freeradbiomed.2025.01.012","volume":"16","author":"S Mikuriya","year":"2025","unstructured":"Mikuriya S (2025) Edaravone mitigates TDP-43 mislocalization in human amyotrophic lateral sclerosis neurons with potential implication of the SIRT1-XBP1 pathway. Free Radic Biol Med 16(230):283\u2013293","journal-title":"Free Radic Biol Med"},{"issue":"10","key":"10_CR19","doi-asserted-by":"publisher","first-page":"3429","DOI":"10.1007\/s10072-023-06869-8","volume":"44","author":"AZ Nourelden","year":"2023","unstructured":"Nourelden AZ (2023) Safety and efficacy of edaravone in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis. Neurol Sci 44(10):3429\u20133442","journal-title":"Neurol Sci"},{"key":"10_CR20","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1056\/NEJMoa1916945","volume":"383","author":"S Paganoni","year":"2020","unstructured":"Paganoni S (2020) Trial of sodium phenylbutyrate\u2013taurursodiol for amyotrophic lateral sclerosis. N Engl J 383:919\u2013930","journal-title":"N Engl J"},{"issue":"1","key":"10_CR21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/mus.27091","volume":"63","author":"S Paganoni","year":"2021","unstructured":"Paganoni S (2021) Long-term survival of participants in the CENTAUR trial of sodium phenylbutyrate-taurursodiol in amyotrophic lateral sclerosis. Muscle Nerve 63(1):31\u201339","journal-title":"Muscle Nerve"},{"issue":"9","key":"10_CR22","doi-asserted-by":"publisher","first-page":"e70360","DOI":"10.1111\/ene.70360","volume":"32","author":"N Calcagno","year":"2025","unstructured":"Calcagno N (2025) Real-world clinical experience with sodium phenylbutyrate and taurursodiol at a single amyotrophic lateral sclerosis center in the United States. Eur J Neurol 32(9):e70360","journal-title":"Eur J Neurol"},{"issue":"4","key":"10_CR23","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s40259-024-00665-2","volume":"38","author":"A Sang","year":"2024","unstructured":"Sang A (2024) Mechanisms of action of the US Food and Drug Administration-approved antisense oligonucleotide drugs. BioDrugs 38(4):511\u2013526","journal-title":"BioDrugs"},{"issue":"3","key":"10_CR24","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-022-00612-2","volume":"22","author":"RJ Mead","year":"2023","unstructured":"Mead RJ (2023) Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translation. Nat Rev Drug Discov 22(3):185\u2013221","journal-title":"Nat Rev Drug Discov"},{"key":"10_CR25","doi-asserted-by":"crossref","unstructured":"Roberts TC (2020) Advances in oligonucleotide drug delivery. Nat Rev Drug Discov 19(10):673\u2013694","DOI":"10.1038\/s41573-020-0075-7"},{"issue":"10","key":"10_CR26","doi-asserted-by":"publisher","first-page":"5235","DOI":"10.1093\/nar\/gkaa299","volume":"48","author":"ST Crooke","year":"2020","unstructured":"Crooke ST (2020) Phosphorothioate modified oligonucleotide-protein interactions. Nucleic Acids Res 48(10):5235\u20135253","journal-title":"Nucleic Acids Res"},{"key":"10_CR27","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.addr.2015.01.008","volume":"87","author":"RS Geary","year":"2015","unstructured":"Geary RS (2015) Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv Drug Deliv Rev 87:46\u201351","journal-title":"Adv Drug Deliv Rev"},{"issue":"41","key":"10_CR28","doi-asserted-by":"publisher","first-page":"5496","DOI":"10.1039\/D0CC00444H","volume":"56","author":"S Epple","year":"2020","unstructured":"Epple S (2020) Consecutive 5\u2032- and 3\u2032-amide linkages stabilise antisense oligonucleotides and elicit an efficient RNase H response. Chem Commun (Camb) 56(41):5496\u20135499","journal-title":"Chem Commun (Camb)"},{"issue":"10","key":"10_CR29","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1021\/acs.accounts.0c00078","volume":"53","author":"P Kumar","year":"2020","unstructured":"Kumar P (2020) DNA analogues modified at the nonlinking positions of phosphorus. Acc Chem Res 53(10):2152\u20132166","journal-title":"Acc Chem Res"},{"key":"10_CR30","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1146\/annurev-pharmtox-010818-021050","volume":"59","author":"CI Edvard Smith","year":"2019","unstructured":"Edvard Smith CI (2019) Therapeutic oligonucleotides: state of the art. Annu Rev Pharmacol Toxicol 59:605\u2013630","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"72","key":"10_CR31","doi-asserted-by":"publisher","first-page":"72ra18","DOI":"10.1126\/scitranslmed.3001777","volume":"3","author":"MA Passini","year":"2011","unstructured":"Passini MA (2011) Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci Transl Med 3(72):72ra18","journal-title":"Sci Transl Med"},{"issue":"8","key":"10_CR32","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1172\/JCI25424","volume":"116","author":"RA Smith","year":"2006","unstructured":"Smith RA (2006) Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest 116(8):2290\u20132296","journal-title":"J Clin Invest"},{"issue":"2","key":"10_CR33","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/jamaneurol.2013.593","volume":"70","author":"L Winer","year":"2013","unstructured":"Winer L (2013) SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapy. JAMA Neurol 70(2):201\u2013207","journal-title":"JAMA Neurol"},{"issue":"5","key":"10_CR34","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/S1474-4422(13)70061-9","volume":"12","author":"TM Miller","year":"2013","unstructured":"Miller TM (2013) An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study. Lancet Neurol 12(5):435\u2013442","journal-title":"Lancet Neurol"},{"issue":"8","key":"10_CR35","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.1172\/JCI99081","volume":"128","author":"A McCampbell","year":"2018","unstructured":"McCampbell A et al. (2018) Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models. J Clin Invest 128(8):3558\u20133567","journal-title":"J Clin Invest"},{"issue":"10","key":"10_CR36","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.3390\/genes15101342","volume":"15","author":"H Moriyama","year":"2024","unstructured":"Moriyama H (2024) Recent progress of antisense oligonucleotide therapy for superoxide-dismutase-1-mutated amyotrophic lateral sclerosis: focus on tofersen. Genes (Basel) 15(10):1342","journal-title":"Genes (Basel)"},{"issue":"2","key":"10_CR37","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2003715","volume":"383","author":"T Miller","year":"2020","unstructured":"Miller T (2020) Phase 1-2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med 383(2):109\u2013119","journal-title":"N Engl J Med"},{"issue":"12","key":"10_CR38","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","volume":"387","author":"TM Miller","year":"2022","unstructured":"Miller TM (2022) Trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med 387(12):1099\u20131110","journal-title":"N Engl J Med"},{"issue":"4","key":"10_CR39","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1007\/s13311-022-01237-4","volume":"19","author":"M Benatar","year":"2022","unstructured":"Benatar M (2022) Design of a randomized, placebo-controlled, phase 3 trial of tofersen initiated in clinically presymptomatic SOD1 variant carriers: the ATLAS study. Neurotherapeutics 19(4):1248\u20131258","journal-title":"Neurotherapeutics"},{"key":"10_CR40","unstructured":"Biogen QALSODY (Tofersen) prescribing information. (2023) https:\/\/www.biogencdn.com\/us\/pdfs\/qalsody-prescribing-information.pdf. Accessed 11 Oct 2025"},{"key":"10_CR41","unstructured":"Meyer T (2024) Clinical and patient-reported outcomes and neurofilament response during tofersen treatment in SOD1-related ALS-A multicenter observational study over 18\u2009months."},{"key":"10_CR42","doi-asserted-by":"crossref","unstructured":"Wiesenfarth M (2024) Effects of tofersen treatment in patients with SOD1-ALS in a \u201cReal-World\u201d setting\u2014a 12-month multicenter cohort study from the German Early Access Program.","DOI":"10.1016\/j.eclinm.2024.102495"},{"key":"10_CR43","doi-asserted-by":"crossref","unstructured":"Simonini C et al (2025) Neurodegenerative and neuroinflammatory changes in SOD1-ALS patients receiving tofersen. Sci Rep 15(1):11034","DOI":"10.1038\/s41598-025-94984-1"},{"issue":"9","key":"10_CR44","doi-asserted-by":"publisher","first-page":"4809","DOI":"10.3390\/ijms25094809","volume":"25","author":"S Cantara","year":"2024","unstructured":"Cantara S (2024) Antisense oligonucleotides (ASOs) in motor neuron diseases: a road to cure in light and shade. Int J Mol Sci 25(9):4809","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10_CR45","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/s1474-4422(24)00216-3","volume":"23","author":"LH van den Berg","year":"2024","unstructured":"van den Berg LH, et al (2024) Safety, tolerability, and pharmacokinetics of antisense oligonucleotide BIIB078 in adults with C9orf72-associated amyotrophic lateral sclerosis: a phase 1, randomised, double blinded, placebo-controlled, multiple ascending dose study. Lancet Neurology 23(9):901\u2013912. https:\/\/doi.org\/10.1016\/s1474-4422(24)00216-3 Epub 2024 Jul 23. PMID: 39059407","journal-title":"Lancet Neurology"}],"container-title":["Methods in Molecular Biology","Gapmers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-5476-7_10","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:02:52Z","timestamp":1790766172000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-5476-7_10"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"ISBN":["9781071654750","9781071654767"],"references-count":45,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-5476-7_10","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"1 October 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}